MA42519A - Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique - Google Patents
Inhibiteur de la pde4 pour le traitement de la néphropathie diabétiqueInfo
- Publication number
- MA42519A MA42519A MA042519A MA42519A MA42519A MA 42519 A MA42519 A MA 42519A MA 042519 A MA042519 A MA 042519A MA 42519 A MA42519 A MA 42519A MA 42519 A MA42519 A MA 42519A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- diabetic nephropathy
- pde4 inhibitor
- pde4
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198213P | 2015-07-29 | 2015-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42519A true MA42519A (fr) | 2018-06-06 |
Family
ID=56551407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042519A MA42519A (fr) | 2015-07-29 | 2016-07-28 | Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200179369A1 (enExample) |
| EP (1) | EP3328381A1 (enExample) |
| JP (1) | JP2018521077A (enExample) |
| CN (1) | CN108135886A (enExample) |
| BR (1) | BR112018001116A2 (enExample) |
| CA (1) | CA2992796A1 (enExample) |
| EA (1) | EA201890346A1 (enExample) |
| MA (1) | MA42519A (enExample) |
| WO (1) | WO2017017165A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179384B2 (en) | 2016-08-26 | 2021-11-23 | Takeda Gmbh | Treatment of nonalcoholic fatty liver disease |
| CN107157999A (zh) * | 2017-05-27 | 2017-09-15 | 青岛海蓝医药有限公司 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
| CN114053281B (zh) * | 2020-08-10 | 2025-05-27 | 成都文鼎科技发展有限公司 | 治疗慢性肾病的方法和药物组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7413751B2 (en) * | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| EP2589599B1 (en) * | 2004-03-03 | 2014-06-25 | Takeda GmbH | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
| GB0504103D0 (en) * | 2005-02-28 | 2005-04-06 | Syngenta Ltd | Novel method |
-
2016
- 2016-07-28 US US15/746,560 patent/US20200179369A1/en not_active Abandoned
- 2016-07-28 JP JP2018503204A patent/JP2018521077A/ja active Pending
- 2016-07-28 MA MA042519A patent/MA42519A/fr unknown
- 2016-07-28 CA CA2992796A patent/CA2992796A1/en not_active Abandoned
- 2016-07-28 EP EP16744758.0A patent/EP3328381A1/en not_active Withdrawn
- 2016-07-28 BR BR112018001116-9A patent/BR112018001116A2/pt not_active Application Discontinuation
- 2016-07-28 CN CN201680056550.2A patent/CN108135886A/zh active Pending
- 2016-07-28 WO PCT/EP2016/067968 patent/WO2017017165A1/en not_active Ceased
- 2016-07-28 EA EA201890346A patent/EA201890346A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018521077A (ja) | 2018-08-02 |
| CA2992796A1 (en) | 2017-02-02 |
| EP3328381A1 (en) | 2018-06-06 |
| WO2017017165A1 (en) | 2017-02-02 |
| BR112018001116A2 (pt) | 2018-09-11 |
| EA201890346A1 (ru) | 2018-08-31 |
| US20200179369A1 (en) | 2020-06-11 |
| CN108135886A (zh) | 2018-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3288592A4 (en) | USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS | |
| EP3370703A4 (en) | GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES | |
| EP3313325A4 (en) | IMPLANTABLE EQUIPMENT FOR THE TREATMENT OF SINUSITIS | |
| IL256209A (en) | Novel cannabinoid combination therapies for multiple myeloma (mm) | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| EP3504187A4 (en) | USE OF PRIDOPIDIN FOR THE TREATMENT OF FUNCTIONAL DECAY | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| EP3374502A4 (en) | METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES | |
| EP3335041A4 (en) | BIOMARKER FOR THE TREATMENT OF ALOPECIA AREATA | |
| EP3362065A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
| EP3383547A4 (en) | ELECTROMAGNETIC MODULES FOR PROCESSING FLUIDS | |
| EP3389645A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3351189A4 (en) | ENDOSCOPE TREATMENT INSTRUMENT | |
| EP3503890A4 (en) | USE OF PRIDOPIDIN FOR THE TREATMENT OF DYSTONIA | |
| EP3328374A4 (en) | GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES | |
| EP3375108A4 (en) | SELECTIVE WIFI | |
| EP3316887A4 (en) | GLS1-INHIBITOR TO TREAT DISEASES | |
| EP3334432A4 (en) | CERDULATINIB FOR THE TREATMENT OF MYELOMA | |
| EP3386967A4 (en) | COMBINATIONS FOR TREATING KIDNEY STONES | |
| EP3349793A4 (en) | ANTI-S100A8 FOR THE TREATMENT OF LEUKEMIA | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| EP3309165A4 (en) | SURFACE TREATMENT AGENT | |
| EP3318205A4 (en) | TREATMENT INSTRUMENT FOR ENDOSCOPE |